Related Experiment Video
Updated: Feb 14, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Mortality in patients with cardiogenic shock treated with the Impella CP microaxial pump for isolated left
Jan-Thorben Sieweke1, Dominik Berliner1, Jörn Tongers1
1Cardiac Arrest Centre and Advanced Heart Failure Unit, Department of Cardiology and Angiology, Hannover Medical School, Germany.
Insights
Early hemodynamic support with Impella CP in cardiogenic shock shows promising results, with lower mortality rates than predicted, especially when cardiac arrest is avoided. Further randomized trials are warranted.
Area of Science:
- Cardiology
- Intensive Care Medicine
- Mechanical Circulatory Support
Background:
- Cardiogenic shock carries a high mortality rate, historically around 50%.
- Intra-aortic balloon pump (IABP) counterpulsation has not demonstrated mortality benefits in previous studies.
- Early invasive hemodynamic support strategies are being explored to improve outcomes.
Purpose of the Study:
- To investigate the effectiveness of an early, interdisciplinary, multiprofessional strategy for hemodynamic support in cardiogenic shock.
- To evaluate the impact of Impella CP microaxial pump use in conjunction with complete revascularization.
- To assess outcomes in patients with cardiogenic shock prior to intensive care unit admission.
Main Methods:
- Analysis of 61 cardiogenic shock patients treated with Impella CP for left ventricle support between 2013 and 2016.
- Inclusion of patients resuscitated before Impella insertion (61%) and comparison with non-resuscitated patients.
- Stratification of patients based on SHOCK-II trial criteria for comparative analysis.
Main Results:
- Overall 30-day mortality was 48% (29/61).
- Mortality was significantly higher in resuscitated patients (65%) compared to non-resuscitated (21%).
- SHOCK-II-eligible patients showed a 30-day mortality of 24%, lower than the trial's ~40% and predicted scores.
Conclusions:
- A standardized protocol with early Impella CP support may improve outcomes in cardiogenic shock with isolated left ventricle failure.
- Pre-implantation cardiac arrest is a critical factor influencing observed mortality.
- The findings support the need for a randomized controlled trial to confirm these results.
Aims:
Cardiogenic shock is still associated with high mortality rates of around 50%. Intra-aortic counterpulsation had been frequently used in cardiogenic shock, but was previously found to provide no mortality benefit. We investigated the effect of an interdisciplinary and multiprofessional routine strategy of early invasive haemodynamic support in combination with complete revascularization in patients with cardiogenic shock before admission to our intensive care unit.
Methods And Results:
We analysed all cardiogenic shock patients (mean age 62±13 years) presenting at our institution between 2013 and mid 2016, who received an Impella CP microaxial pump for isolated left ventricle support (n=61). Sixty-one per cent (n=37) had been resuscitated before Impella insertion. Overall mortality was 48% (n=29/61) at 30 days. Thirty-day mortality was higher in resuscitated patients (resuscitated: 65% (n=24/37); non-resuscitated: 21% (n=5/24)). When applying the inclusion/exclusion criteria of the SHOCK-II trial, eligible patients (n=25) had a markedly lower mortality (24% (n=6/25) at 30 days) compared with the published trial (~40% in both arms). The observed mortality of SHOCK-II-like patients in the registry was also lower compared with their predicted mortality using IABP-Shock II score (49%) and CardShock score (36%).
Conclusion:
The results of this registry suggest that using a standardized protocol including early active haemodynamic support with Impella CP in cardiogenic shock in patients with isolated left ventricle failure may be associated with improved outcomes and lower than previously reported or predicted mortality rates. Pre-implantation cardiac arrest critically influences observed mortality. The results support the case for a randomized trial.
More Related Videos
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
09:40Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
Published on: May 13, 2019
Related Concept Videos
ATP Driven Pumps III: V-type Pumps
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
Shock Waves
When the source's speed approaches the speed of sound, constructive interference between successive wavefronts emitted by the source occurs immediately behind it. Initially, scientists believed that this constructive interference would result in such high...
ATP Driven Pumps II: P-type Pumps
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
Pumped Concrete
For direct-acting pumps, the concrete enters the pump via the inlet valve under the action of gravity and suction created by the movement of the piston. This concrete is then forced into the pipeline and out through the outlet valve by the forward movement...
Refrigerators and Heat Pumps
A household refrigerator removes heat from...
Pathophysiology of Heart Failure